Replies to post #480567 on Anavex Life Sciences Corp (AVXL)

[Hosai]

Well in terms of that silly topic why do you think Donnanemab does not have the same EMA indication wording Blarcamesine has of "Treatment of Alzheimers disease and dementia" and instead has "To slow disease progression in adult patients with Alzheimer disease".

Both descriptions were added for the first time today as previouly Donnaemabs EMA indication each month for 2024 has always simply said "psychoanaleptics".

[sab63090]

Investor

I agree that the data is not there and does not follow normal medical protocols....I might get a lot wrong, but Missling dropped the ball after hyping up this presentation! The only people applauding were probably the members on his team. I will report if the person I contacted attended, I'm kind of afraid of what she will say.

[Hoskuld]

Silly neurologists! 58 silly, silly doctors. Silly OLE data. Silly brain shrinkage data. So much silliness.

[frrol]

Re the OLE trial, people should compare its Secondary Outcome Measures (clinicaltrials.gov) to Missling's TLR, i.e. what was pre-specified (and very sensible, straightforward, and important) vs what was disclosed. Shades of his AUC and Odds Risk spinning.

I think Grimmer is presenting the OLE results at the PD/AD. We'll have to wait 10 weeks and see if he discloses the Secondaries, per trial protocol.